DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Yu ML, Hung CH, Cheng PN. et al.
An open-label, randomized, active-control trial of 8-week versus 12-week elbasvir/grazoprevir in nave HCV genotype-1b patients with mild fibrosis (EGALITE).
Journal of gastroenterology and hepatology 2018;
33: 136-136
We do not assume any responsibility for the contents of the web pages of other providers.